Search for Terms or Answers
Cancer is a major cause of mortality in systemic sclerosis (SSc). A nested case-control study within EUSTAR registry shows distinct patterns of cancer related temporally to SSc, serologic profiles and traditional cancer risk factors.
Cancers were
The FDA and Priovant recently annouced approval of brepocitinib (Lisraya), a JAK1/TYK2 inhibitor, for the indication of adults with dermatomyositis (DM). This is the first oral (once daily) agent approved for DM.
Read Article
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. Take this week's RheumIQ and test your knowledge!
Read Article
RheumNow recentlty surveyed rheumatologists about Sjogren’s disease (SjD) - how they approach diagnosis, treatment, and unique challenges; all important as new advances in SjD evolves.
Read Article
A secondary analysis of the VALOR trial has shown that the TYK2/JAK1 inhibitor brepocitinib was effective at cutaneous disease activity outcomes, delivering rapid, clinically meaningful, and remission-level control of cutaneous dermatomyositis (DM).
Read Article
Postural orthostatic tachycardia syndrome (POTS) is a chronic autonomic disorder affecting an estimated 0.1%–1% of the US population, with peak incidence at ages 13–29 and a striking 90% female predominance.
Read Article
A EUVAS-sponsored expert panel of 37 specialists across rheumatology, nephrology, dermatology and pathology has published evidence-based guidelines for adult-onset IgA vasculitis (IgAV), which behaves very differently in adults compared to usually self-limited childhood form.
Read Article
This review article addresses the recognition, prevention and management of glucocorticoid toxicity in rheumatic patients.
Read Article
Dr. Cush reviews the news and journal articles from this past week on RheumNow.com; talking about lumbar belts, scholarships and misdiagnosis.
Read Article
The rheumatology and scleroderma communities mourn the loss of Dr. Thomas A. Medsger Jr., who died August 15, 2026, in Pittsburgh, at age 89.
Read Article
RA confers a 50–100% excess risk of venous thromboembolism (VTE) compared with the general population, with adjusted hazard/odds ratios ranging from 1.3–2.2 across large cohort studies (Vojinovic, Askling, Antovic; Rheumatology, 2026).
Read Article
Shoulder pain affects 16% of adults annually and is the third most common musculoskeletal presentation in primary care. This new review reframes the diagnostic and therapeutic approach, moving away from pathoanatomic labels (rotator cuff tendinopathy, impingement, bursitis) toward the umbrella
Read Article
Today Argenx announced the results of their Phase 3 "ALKIVIA" study; demonstrating efficacy and safety of subcutaneous efgartigimod for Idiopathic Inflammatory Myopathy (IIM, AKA inflammatory myositis).
Read Article
Dr. Jack Cush reviews Gout in this continuing series for Advanced Practice Rheum. Review the companion slide deck here.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
